globenewswire

American Heart Association's Go Red For Women(R) Movement to Ring The NASDAQ Stock Market Opening Bell Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 06:11
ADVISORY--What:  To kick off American Heart Month and to gear up for National Wear Red Day, American Heart Association's Go Red For Women® movement will visit the NASDAQ MarketSite in Times Square on Wednesday, February 5th.
Read more...
 
ResCare, Inc. to Hold Conference Call on February 19, 2014 Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 06:00
LOUISVILLE,Ky.--ResCare, Inc. today announced that it will hold a conference call on Wednesday, February 19, 2014, at 9:00 a.m. Eastern time to discuss its financial results for the fourth quarter and year ended December 31, 2013.
Read more...
 
Child Care Aware(R) of America Announces 2014 Symposium Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 05:50
ARLINGTON, VA.--Child Care Aware ® of America's 2014 Symposium will take place April 2-4, 2014 at the Hyatt Regency Washington on Capitol Hill in Washington D.C.
Read more...
 
MedMal Direct Announces Its Endorsement by Physicians' Alliance of America Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 05:32
JACKSONVILLE, Fla.--Jacksonville-based MedMal Direct Insurance Company (MedMal Direct) announces its recent endorsement by Physicians' Alliance of America.
Read more...
 
Dr. Bernard Arocha Opens Arocha Hair Restoration Office in Austin, Texas Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 04:44
AUSTIN, Texas--Dr. Bernard Arocha, founder of Arocha Hair Restoration (www.arochahairrestoration.com), a leading provider of surgical hair transplants and medical treatment of hair loss, today announced the opening of a new Austin, Texas office.
Read more...
 
Merit Medical Systems to Announce Fourth Quarter and Year End Results on February 24, 2014 Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 03:30
SOUTH JORDAN, Utah--Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and
endoscopy, announced today that the Company will release its financial results for the fourth quarter and year ended December 31, 2013, after the close of the stock market on Monday, February 24th, 2014.
Read more...
 
Context Matters to Participate in Webinar With Oracle Health Sciences and

Error. Page cannot be displayed. Please contact your service provider for more details. (12)

Tufts Center for the Study of Drug Development on Integration of Real-World Data in Drug Development Strategy
Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:45
NEW YORK--Context Matters announces that its CEO, Yin Ho, MD, MBA, will participate in a webinar sponsored by Oracle Health Sciences and Pharmaceutical Executive magazine called "Transforming Clinical Development Strategy and Performance with Real-World Data" on February 13, 2014.
Read more...
 
PositiveID Corporation Adds U.S. Homeland Security and Counter-Terrorism Expert Thomas DiNanno to Its Advisory Board Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:30
DELRAY BEACH, Fla.--PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced it has added Thomas DiNanno to its Advisory Board.
Read more...
 
Lipocine to Present at the 2014 Leerink Global Healthcare Conference Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:30
SALT LAKE CITY--Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday February 12, 2014 at 10:15 a.m. EST.
Read more...
 
Hemispherx Biopharma Summarizes Clinical Results Presented in Washington, DC on January 30, 2014 in Conjunction with the American Society for Microbiology (ASM) Biodefense Conference Aimed at Developing a Universal Influenza Vaccine to Prevent Pandemic In Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:30
PHILADELPHIA--Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), presented a summary of the results of its Phase I/II study from the poster presentation entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen®), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" given at the American Society for Microbiology (ASM) Biodefense Conference in Washington, DC on January 30, 2014.
Read more...
 
Premier, Inc. Introduces Enterprise-Wide Analytics Solution to Improve Operational Performance, Population Health Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:26
CHARLOTTE, N.C.--Premier, Inc. (Nasdaq:PINC) has introduced an enterprise-wide analytics solution enabling hospitals and health systems to easily access, integrate and interpret their data, any way they want to.
Read more...
 
Enzymotec Ltd. to Report Fourth Quarter and Fiscal Year 2013 Financial Results Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:24
MIGDAL HA'EMEQ, Israel--Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2013 on Thursday, February 13, 2014, before the market opens.
Read more...
 
IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:05
SAINT LAURENT, Quebec--IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage drugs, today announced that they received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding the New Drug Application ("NDA") for their VersaFilm™ Oral Film Product for the treatment of acute migraines.
Read more...
 
RedHill Biopharma and IntelGenx Receive Complete Response Letter From FDA for RHB-103 Oral Film for Acute Migraines Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:00
TEL-AVIV, Israel--RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage drugs, together with IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that they received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding the New Drug Application ("NDA") for RHB-103 for the treatment of acute migraines.
Read more...
 
Cleveland BioLabs to Present at 2014 BIO CEO & Investor Conference Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 04 February 2014 02:00
BUFFALO, N.Y.--Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the 2014 BIO CEO & Investor Conference, February 10-11, in New York, NY.
Read more...
 
<< Start < Prev 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 Next > End >>

Page 1521 of 1558

Newsletter

BMR:1